Mr Renaud Prudent

Renaud joined Edelris in 2018 as the Head of Screening Technologies, where he pioneered the development of AS-MS technologies.
Prior to this, Renaud served as the Chief Operating Officer at Cellipse, a drug discovery start-up company that he co-founded.
During his post-doc time, Renaud developed and applied different screening approaches in the oncology area, for example synthetic lethality and drug enhancers.
He obtained a Ph.D. in chemical biology from the Université Grenoble Alpes, where he worked on the screening of allosteric kinase inhibitors.
He has co-authored over 25 publications and patents.